Distinct Pathways, Shared Progress: Metabolic/Genetic Disorders & Biliary Physiology | AASLD

Distinct Pathways, Shared Progress: Metabolic/Genetic Disorders & Biliary Physiology

Description

This session highlights innovations from molecular mechanisms to drug development and clinical trials in biliary physiology and genetic and metabolic conditions. This session will spotlight cholangiocyte biology from scaffolding to repair. These research presentations will provide insights into mechanisms and therapeutics for A1AT deficiency, Wilson Disease, and hemachromatosis. 

Journey Maps

Presentations

8:00 AM - 8:15 AM
Oct 09 2026
Convention Center - Room 145, Level 1

Generation of Macro-Scale Functional Biliary Trees with Primary Cilia and Enhanced Injury Resistance

Pavel Strnad, MD , Abstract Presenter
Basic Science
8:15 AM - 8:30 AM
Oct 09 2026
Convention Center - Room 145, Level 1

Fazirsiran is effective in early and advanced fibrosis in patients with alpha-1 antitrypsin deficiency-associated liver disease

Pavel Strnad, MD , Abstract Presenter
Basic Science
8:30 AM - 8:45 AM
Oct 09 2026
Convention Center - Room 145, Level 1

Inducible dual loss of β- and γ-catenin in bile ducts leads to cholestatic injury and mortality or repair based on the extent of cell junction loss  

Vik Meadows, PhD , Abstract Presenter
Basic Science
8:45 AM - 9:00 AM
Oct 09 2026
Convention Center - Room 145, Level 1

New insights into pathogenic mechanisms of liver fibrosis in hemochromatosis

Grace L Guo, MBBS, PhD , Abstract Presenter
Basic Science
9:00 AM - 9:15 AM
Oct 09 2026
Convention Center - Room 145, Level 1

Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline

Pavel Strnad, MD , Abstract Presenter
Basic Science
9:15 AM - 9:30 AM
Oct 09 2026
Convention Center - Room 145, Level 1

Artificial intelligence-based qFibrosis® analysis correlates with changes in histological features in alpha-1 antitrypsin deficiency-associated liver disease following treatment with fazirsiran

Grace L Guo, MBBS, PhD , Abstract Presenter
Basic Science

Objectives

  • Evaluate emerging therapies for metabolic and genetic liver disease.
  • Describe basic science mechanisms of cholangiocyte development and repair and their implications for therapeutic targets.
  • Discuss basic, translational, and clinical studies for treatment of biliary disorders and genetic/metabolic liver disease.